Companies Reluctant To Put Combo Drugs Through NICE, UK Breast Cancer Charity Warns
Companies are delaying putting their combination products through NICE, the health technology appraisal institute for England and Wales, warns the UK charity Breast Cancer Now.
You may also be interested in...
HTA body NICE is exploring whether competition law impacts pricing of combination drugs in UK.
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.